Monday
09.00 - 15.50
Vienna

Advancing diabetes treatment: new standards in patient-centered care

INCREASING OPPORTUNITY FOR INDIVIDUALISED CARE WITH AN ORAL GLP-1RA

Tina Vilsbøll (Denmark)
Innovation in the GLP-1RA landscape: expanding options for individualised care
Juris Meier (Germany)
An oral GLP-1RA in the incretin landscape
Richard Pratley (USA)
Navigating the evolving treatment landscape: head-to-head comparisons
All
Clinical perspectives: realising the clinical potential for an oral GLP-1RA diabetes treatment

OPTIMISING THE TREATMENT OF VULNERABLE PATIENTS WITH DIABETES

Ofri Mosenzon (Israel)
The vulnerable patient: the use of semaglutide in renal impairment and late stage disease
Stephen Bain (UK)
Diving deeper into the PIONEER programme: exploring different patient populations
All
Clinical perspectives: addressing treatment for the vulnerable diabetes patient

BEYOND GLYCAEMIC CONTROL: NEW DIRECTIONS IN PATIENT-CENTERED CARE

Alice Cheng (Canada)
Across the continuum of care: efficacy with once-weekly semaglutide
David Strain (UK)
Addressing the needs of patients beyond glycaemic control: effects of once-weekly semaglutide
Nikolaus Marx (Germany)
Changing treatment guidelines: new developments and clinical perspectives
All
Clinical perspectives: implications of evolving guidelines for patient care

INNOVATIONS IN INSULIN TREATMENT: NEW OPPORTUNITIES FOR PATIENT-CENTERED CARE

Eden Miller (USA)
Glycaemic control: the story untold by HbA1c
Julio Rosenstock (USA)
Raising the bar for innovation with weekly basal insulin
All
Clinical perspectives: what does innovation in insulin therapy mean for patient outcomes?
Marcus Schindler (Novo Nordisk)
What’s on the horizon: early pipeline innovation in diabetes
Symposium by:
Novo Nordisk A/S